Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Dirui Industrial

DIRUI Industrial Co., Ltd provides laboratory equipment and clinical diagnostic reagents for the in-vitro diagnostic ... read more Featured Products: More products

Download Mobile App





DIRUI Presents High-End Diagnostic Systems for Hospitals and High-Volume Labs at EUROMEDLAB 2022

By Carolyn Moody, RN - News Editor
Posted on 12 Apr 2022

DIRUI Industrial Co. More...

, Ltd. (Jilin, China) presented its high-end diagnostic systems, including hematology, chemiluminescence immunoassay, chemistry and urinanalysis analyzers, for hospitals and high-volume labs at EUROMEDLAB 2022.

DIRUI demonstrated its BF-7200Plus automatic hematology analysis system which has a maximum throughput of 480 tests per hour and measures 37 parameters (including RET detection), five scattergrams and two histograms. It performs optical analysis for WBC measurement and comes with pathology and morphology abnormality alarms. DIRUI also demonstrated its new CM180 chemiluminescence immunoassay analyzer with a throughput of up to 180 tests/hour and walk-away time of up to 2.5 hours. The CM180 has time to first result of only 15 minutes and allows 25 items to be tested at the same time. Featuring a user-friendly design to keep test results accurate and reliable, the CM180 analyzer provides the best solution for laboratory chemiluminescence immunoassay.

Also on display at EUROMEDLAB 2022 was DIRUI’s CS-T240Plus automatic chemistry analyzer which offers the ultimate in convenience, performance and confidence for small to medium size laboratories. The powerful desktop analyzer has a maximum throughput of 240 tests/hour at constant speed and 480 tests/hour for ISE. It uses whole blood samples to test for HbA1c, ensuring more accurate results and has a water consumption of only three liters per hour. This automated random access clinical chemistry analyzer can be easily integrated with any type of laboratories for routine, emergency analysis. In addition, DIRUI showcased its MUS-3600 automatic urinanalysis system with a flexible combination of modules and super fast detection speed. It has a throughput of up to 480 tests per hour (for hybrid) and allows up to 580 urine samples to be loaded at one time. Using leading detection methodologies, the MUS-3600 can provide objective and quantitative report information, clear and visible particle image information, and three key clinical information - red blood cell morphology information, urinary tract infection information, and urine culture information.

Related Links:
DIRUI Industrial Co., Ltd. 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.